Market revenue in 2023 | USD 145.7 million |
Market revenue in 2030 | USD 295.7 million |
Growth rate | 10.6% (CAGR from 2023 to 2030) |
Largest segment | Epinephrine |
Fastest growing segment | Immunotherapies |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Antihistamines, Epinephrine, Immunotherapies, Other Drug Class |
Key market players worldwide | Nestle SA, Sanofi SA, DBV Technologies SA ADR, PureTech Health PLC, Regeneron Pharmaceuticals Inc, Teva Pharmaceutical Industries Ltd ADR, Protagonist Therapeutics Inc, Aravax, Alladapt Immunotherapeutics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to peanut allergy treatment market will help companies and investors design strategic landscapes.
Epinephrine was the largest segment with a revenue share of 47.43% in 2023. Horizon Databook has segmented the Europe peanut allergy treatment market based on antihistamines, epinephrine, immunotherapies, other drug class covering the revenue growth of each sub-segment from 2018 to 2030.
In Europe, a noteworthy development in peanut allergy treatment has emerged, with the NHS in England taking a significant step by introducing a treatment, Palforzia, in December 2021. This treatment was designed to help individuals build tolerance to peanuts, reducing the severity of symptoms, including potentially life-threatening anaphylaxis.
Over the last decade, the prevalence of peanut allergies among children in Western countries doubled, according to Allergy UK. The symptoms of peanut allergy can range from hives, swelling, and itching to stomach cramps, nausea, & throat tightening. Peanuts or traces of them can be found in a wide range of foods, from cereals to chocolates.
However, children and young people between the ages of 4 and 17 are now set to receive a novel treatment, allowing them to lead more normal lives without the constant fear of accidental peanut exposure. Clinical trials have shown significant improvements, and this initiative promises to have a positive impact on patients & their families.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe peanut allergy treatment market , including forecasts for subscribers. This continent databook contains high-level insights into Europe peanut allergy treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account